Histone deacetylases (HDACs) are promising targets for cancer therapy, and first-generation HDAC inhibitors are currently in clinical trials for the treatment of cancer patients. HDAC6, which is a key regulator of many signaling pathways that are linked to cancer, has recently emerged as an attractive target for the treatment of cancer. In the present study, HDAC6 was found to be overexpressed in lung adenocarcinoma cell lines and was negatively correlated with the prognosis of patients with lung adenocarcinoma. Overexpression of HDAC6 promoted the proliferation of lung adenocarcinoma cells in a deacetylase activity-dependent manner. HDAC6 overexpression conferred resistance to gefi-tinib via the stabilization of epidermal growth factor receptor (EGFR). The inhibition of HDAC6 by CAY10603, a potent and selective inhibitor of HDAC6, inhibited the proliferation of lung adenocarcinoma cells and induced apoptosis. CAY10603 downregulated the levels of EGFR protein, which in turn inhibited activation of the EGFR signaling pathway. Moreover, CAY10603 synergized with gefitinib to induce apoptosis of the lung adenocarcinoma cell lines via the destabilization of EGFR. Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of lung adenocarcinoma.
Lung cancer is the leading cause of cancer-related death worldwide and accounts for more than one million deaths per year (1). The morbidity of lung cancer has continued to increase worldwide, particularly in developing countries, which is partly due to air pollution. Lung cancer can be divided into two histological types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be further subdivided into: lung adenocarcinoma, large cell carcinoma and squamous cell carcinoma. These cancer subtypes have distinct morphologies and molecular profiles, and arise from distinct locations within the lung. Approximately 40% of lung cancers are adenocarcinomas. Despite advances in the diagnosis and treatment of lung adenocarcinoma, the 5-year overall survival rate of patients with lung adenocarcinoma is still extremely low (2). In recent years, great achievements have been made in our understanding of lung adenocarcinoma driver gene mutations and rearrangements, which play critical roles in tumor development and progression (3). Among them, somatic mutations in the gene that encodes the epidermal growth factor receptor (EGFR) and rearrangements that involve the gene that encodes anaplastic lymphoma kinase (ALK), are the most well-characterized examples (4,5). Large, prospective randomized trials have shown that molecularly selected patients with advanced lung adenocarcinoma can benefit from treatment with EGFR and ALK tyrosine kinase inhibitors (TKIs). However, despite the success of such agents in the treatment of genetically defined subsets of lung cancer, mutations such as those in EGFR and rearrangements within the ALK gene are identified in only a limited number of patients (6). Moreover, the majority of patients who initially respond to EGFR-TKI therapy develop acquired resistance within 6–12 months (5). Therefore, further research is needed to identify new therapeutic targets and tools for the treatment of lung adenocarcinoma.
Histone deacetylases (HDACs) are enzymes that modulate the acetylation status of histones and other important cellular proteins (7). Eighteen HDACs have been identified in humans, and these enzymes are divided into four classes, as follows, based on sequence phylogeny and function: class I (HDAC1, 2, 3 and 8), class II (HDAC4, 5, 6, 7, 9 and 10), class III (SIRT1-7) and class IV (HDAC11) (8). HDACs have been recognized as potentially useful therapeutic targets for a broad range of human disorders including cancer (8,9). HDACs are considered to be among the most promising targets in drug development for cancer therapy. Two HDAC inhibitors, SAHA (vorinostat) and romidepsin (FK228), have been approved by the US Food and Drug Administration for the treatment of cutaneous T cell lymphoma (10,11). However, these inhibitors elicit profound side-effects since they target several HDAC isoforms (12,13). Isoform-selective HDAC inhibitors may offer a therapeutic advantage due to minimal toxicity. Among the 18 HDACs, HDAC6 has recently sparked great interest due to its functional role in tumor progression. HDAC6 is a key regulator of many signaling pathways that have been linked to cancer (14,15). A diverse set of HDAC6 substrates is involved in tumorigenesis, such as Hsp90, α-tubulin and cortactin. Deacetylation of the Hsp90 core component by HDAC6 activates the chaperone activity of Hsp90 and stabilizes Hsp90-associated molecules including EGFR, Akt, c-Raf, FLT3 and mutant p53 (16). HDAC6 can promote cell migration through the deacetylation of α-tubulin (17). HDAC6 has been shown to regulate the cell cycle, apoptosis, and metastasis, among other cellular processes (18,19). However, unlike the inhibition of other HDACs, the inhibition of HDAC6 is not believed to be associated with severe toxicity, which makes HDAC6 a possible target for the treatment of cancer. However, few studies have been conducted in regards to the role of HDAC6 in lung adenocarcinoma.
In the present study, HDAC6 was found to be overexpressed in lung adenocarcinoma cell lines, and the overexpression of HDAC6 promoted lung adenocarcinoma proliferation and conferred resistance to gefitinib, a widely used EGFR-TKI, in a deacetylase activity-dependent manner. The inhibition of the deacetylase activity of HDAC6 by CAY10603 (20), a potent and selective HDAC6 inhibitor, inhibited the proliferation and induced th apoptosis of lung adenocarcinoma cell lines. CAY10603 synergized with gefitinib to induce the apoptosis of lung adenocarcinoma cells via the destabilization of EGFR. Our results suggest that inhibition of HDAC6 may be a promising strategy for the treatment of lung adenocarcinoma.
Materials and methodsCell culture
The human lung adenocarcinoma cell lines A549, HCC827 and H1975 were obtained directly from the American Type Culture Collection (ATCC; Manassas, VA, USA). The cell lines were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
Antibodies and reagents
CAY10603 and gefitinib were purchased from Selleck (Houston, TX, USA). The anti-PARP (9542) and anti-BID (2002) antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). The anti-caspase 3 (EAP0893) antibody was purchased from Elabscience (Wuhan, Hubei, China). The anti-p53 (ab179477), anti-Bax (ab32503), anti-EGFR (ab52894) and anti-p-ERK (ab76299) antibodies were purchased from Abcam (Cambridge, MA, USA). The anti-HDAC6 (12834-1-AP), Bcl2 (12789-1-AP), Bcl-xL (10783-1-AP), Mcl1 (16225-1-AP), p21 (10355-1-AP) and ERK1/2 (16443-1-AP) antibodies were obtained from Proteintech (Chicago, IL, USA). The anti-β-actin mouse monoclonal antibody was purchased from Abgent (San Diego, CA, USA).
Cell proliferation and colony formation assays
In regards to the cell proliferation assay, cells that were cultured in 96-well plates were treated with the indicated compounds, and cell proliferation was measured at the indicated times by the Cell Counting Kit-8 (CCK-8) (Dojindo, Tokyo, Japan) assay. In regards to the colony formation assay, cells were seeded at 1,000/well into 6-well plates and were cultured over a 14-day period. Colonies were fixed in 4% paraformaldehyde, washed with H2O and stained with 0.1% crystal violet.
Annexin V assay of cell apoptosis
Cells were cultured in 6-well plates and were treated with the indicated compounds, trypsinized and collected. The collected cells were washed with PBS, resuspended in binding buffer, and stained with Annexin V-PE and 7-AAD for 15 min according to the manufacturer's protocol from Becton-Dickinson (San Jose, CA, USA). Fluorescence was estimated with a Becton-Dickinson flow cytometer.
Plasmids and transfection
The plasmids that express wild-type HDAC6 (HDAC6 WT) and deacetylase-deficient HDAC6 (HDAC6 MT) were kindly provided by Professor Jun Zhou of Nankai University (21,22). The plasmids were transfected into cells with TurboFect DNA transfection reagent (Thermo Scientific, Waltham, MA, USA). Control siRNA and siRNAs targeting human HDAC6 were purchased from RiboBio (Guangzhou, China). siRNA was transfected into cells using Lipofectamine RNAiMAX from Invitrogen (Waltham, MA, USA).
Western blotting
Cells were lysed in lysis buffer (Beyotime, Jiangsu, China). The samples were electrophoresed by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Roche). The membranes were blocked with 5% dried skim milk and then incubated with the indicated primary antibody followed by incubation with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (Proteintech). Finally, the bands were visualized with WesternBright ECL HRP substrate (Advansta, Menlo Park, CA, USA) and developed with Kodak film.
Statistical analysis
Statistical analysis was performed using the Student's t-test. Data are expressed as the mean ± standard deviation (SD). P<0.05 was considered to indicate a statistically significant difference.
ResultsHDAC6 is overexpressed in lung adenocarcinoma and is negatively correlated with the prognosis of patients with lung adenocarcinoma
It has been reported that expression of HDAC6 protein is upregulated in several types of human cancers, but the role of HDAC6 in lung adenocarcinoma tumorigenesis is still unknown (19). To determine the expression level of HDAC6 protein in lung adenocarcinoma, we first compared the expression of HDAC6 between lung adenocarcinoma cell lines and a normal human lung cell line. Three lung adenocarcinoma cell lines (A549, HCC827 and H1975) and one normal human lung cell line (BEAS-2B) were tested. As shown in Fig. 1A, HDAC6 was overexpressed in the lung adenocarcinoma cell lines compared with the normal lung cell line. Moreover, following the search of an online Kaplan-Meier plotter database, and analysis of the prognostic value of biomarkers using transcriptomic data in NSCLC (23), we found that the expression of HDAC6 was negatively correlated with the prognosis of patients with lung adenocarcinoma (P<0.01) (Fig. 1B).
HDAC6 promotes the proliferation of lung adenocarcinoma cells in a deacetylase activity-dependent manner
Since HDAC6 is overexpressed in lung adenocarcinoma, we speculated that HDAC6 may regulate the proliferation of lung adenocarcinoma cells. To assess the effects of HDAC6 on cell proliferation and whether this is dependent on its deacetylase activity, A549 and HCC827 cells were transfected with wild-type HDAC6 (HDAC6 WT) and the catalytically inactive H216A/H611A mutant HDAC6 (HDAC6 MT) overexpression plasmids, and cell proliferation was measured by CCK-8 assay. We found a significant increase in the cell proliferation rate on day 4 when HDAC6 was upregulated (Fig. 2A and B). Moreover, the HDAC6 MT-transfected group showed nearly the same proliferation rate as the control group (Fig. 2A and B). Conversely, knockdown of HDAC6 led to impaired cell proliferation in both cell lines (Fig. 2C and D). These results indicate that HDAC6 promotes cell proliferation of lung adenocarcinoma in a deacetylase activity-dependent manner.
HDAC6 confers resistance to gefitinib-mediated killing of lung adenocarcinoma cells
Dramatic clinical responses to the selective EGFR-TKIs gefitinib and erlotinib have been observed in patients with advanced lung adenocarcinoma, particularly in those with tumors that harbor activating EGFR mutations (1). Gefitinib was the first small-molecule EGFR-TKI that received FDA approval in 2003. However, almost all tumors develop acquired resistance to these TKIs within 9–15 months (24). EGFR-TKIs are used to treat lung adenocarcinomas that carry activating EGFR mutations, whereas they exert only modest antitumor activity in lung adenocarcinomas that express wild-type EGFR. In the present study, we showed that the overexpression of HDAC6 remarkably impaired gefitinib efficiency with respect to the inhibition of cell proliferation of the lung adenocarcinoma cell lines A549 (EGFR WT) and HCC827 (EGFR DelE746A750) in a deacet-ylase activity-dependent manner (Fig. 3A and B). Knockdown of HDAC6 also sensitized the A549 and HCC827 cells to geftinib (Fig. 3C and D). Furthermore, by Annexin V staining and western blotting, the cleavage of PARP and caspase 3 was detected and showed that HDAC6 overexpression conferred resistance to gefitinib-induced apoptosis, which was dependent on the deacetylase activity of HDAC6 (Fig. 4A–C). Our results suggest that the overexpression of HDAC6 may be an intrinsic mechanism that confers resistance to EGFR-TKIs.
Inhibition of HDAC6 deacetylase activity by CAY10603, a selective HDAC6 inhibitor, inhibits the proliferation of lung adenocarcinoma cells
The above data indicated that HDAC6 plays a relevant role in the control of lung adenocarcinoma cell proliferation. To further assess this possibility, we tested the effect of HDAC6 inhibition on lung adenocarcinoma cell lines using a potent and selective inhibitor, CAY10603 (chemical structure shown in Fig. 5A). We assessed the growth inhibition in response to CAY10603 treatment in two human lung adeno-carcinoma cell lines: A549 and HCC827. A dose-dependent decrease in cell proliferation was observed for both cell lines tested (Fig. 5B and C). The same conclusion was drawn from the results of the clone formation assay. We noted a significant decrease in clone numbers of the lung adenocarcinoma cell lines after CAY10603 treatment (Fig. 5D).
Inhibition of HDAC6 by CAY10603 notably induces apoptosis of lung adenocarcinoma cells
Given that CAY10603 inhibits the proliferation of lung adenocarcinoma cell lines, we investigated its effect on apoptosis. CAY10603 clearly induced apoptosis in the lung adenocarcinoma cell line A549 (Fig. 6A). We determined the effects of CAY10603 on the activation of caspases and Bid proteins as well as its effect on PARP cleavage, which serves as a marker of apoptosis. Western blot analysis demonstrated that PARP, Bid and caspase 3 were cleaved following CAY10603 treatment in the A549 cells (Fig. 6B). Protein levels of the apoptosis-related proteins were also detected (Fig. 6C). The inhibition of HDAC6 by CAY10603 increased the levels of pro-apoptotic proteins such as BAX and p21 (Fig. 6C). CAY10603 also led to decreases in the levels of anti-apoptotic proteins including Bcl2 and Bcl-xL (Fig. 6C).
Inhibition of HDAC6 synergizes with gefitinib to induce apoptosis in lung adenocarcinoma cell lines, partly through the destabilization of EGFR and inactivation of the EGFR pathway
Since HDAC6 overexpression confers resistance to gefitinib, we speculated that the inhibition of HDAC6 may contribute to an increase in the efficiency of gefitinib with respect to lung adenocarcinoma cells. To examine whether a cooperative effect exists between CAY10603 and gefitinib in the chemotherapeutic treatment of lung adenocarcinoma, we treated A549 cells with CAY10603 and gefitinib either alone or in combination. In agreement with our hypothesis, the co-treatment of CAY10603 and gefitinib significantly reduced the cell viability of the gefitinib-resistant cell line A549 (Fig. 7A). The rate of apoptosis was also increased after the co-treatment of these two drugs, as evidenced by increases in the number of Annexin V-positive cells (Fig. 7B and C). An increase in apoptosis by this combination drug treatment was further evidenced by the cleavage of PARP and caspase 3 (Fig. 7D). We also observed that the combination of CAY10603 and gefitinib remarkably inhibited the clono-genic survival of the A549 cells (Fig. 7E). These data suggest that the combination treatment of CAY10603 and gefitinib displayed a significant synergistic therapeutic effect in lung adenocarcinoma. Next, we aimed to ascertain the mechanism by which CAY10603 contributes to the gefitinib-induced cell death of lung adenocarcinoma cells. HDAC6 has been shown to be an important regulator of EGFR endocytic trafficking and degradation (25,26). To test whether HDAC6 regulates EGFR stability in lung adenocarcinoma cells, the cells were transfected with control or HDAC6 overexpression plasmids for 48 h, and then the cells were lysed and EGFR protein levels were detected by western blotting. We found that overexpres-sion of HDAC6 in lung adenocarcinoma cell lines stabilized EGFR in a deacetylase activity-dependent manner (Fig. 8A). Conversely, knockdown of HDAC6 led to destabilization of EGFR (Fig. 8B). Thus, the inhibition of HDAC6 may also destabilize EGFR and inhibit activation of the EGFR pathway. CAY10603 treatment destabilized EGFR and inhibited activation of the EGFR pathway in the A549 and HCC827 cells. ERK, a well-known EGFR target, was selected as a symbol of EGFR activation (Fig. 8C). We also found that the activation of ERK was inhibited by the combination of CAY10603 and gefitinib compared with the administration of either inhibitor alone (Fig. 8D). Taken together, our results showed that inhibition of HDAC6 synergized with gefitinib to induce apoptosis in lung adenocarcinoma via destabilization of EGFR and inactivation of the EGFR pathway.
Discussion
HDACs are enzymes that are involved in the regulation of the acetylation of histone and non-histone proteins. Protein acetylation has emerged as an important post-translational modification that regulates multiple cellular functions, including chromatin remodeling and transcriptional regulation, microtubule dynamics, metabolism, autophagy and apoptosis (7,12). HDACs are considered to be among the most promising targets for cancer therapy, and first-generation HDAC inhibitors are currently being tested in phase I/II clinical trials (9). SAHA and romidepsin have already been approved by the US FDA for the treatment of cutaneous T cell lymphoma. As a cytoplasmic HDAC, HDAC6 has been shown to deacetylate a diverse set of substrates that are involved in tumorigenesis, including Hsp90, α-tubulin and EGFR (16,25,26). HDAC6 has also been implicated in the regulation of many cancer-associated cellular events and signaling pathways, which makes it an attractive target for cancer therapy (27). HDAC6 has been shown to contribute to the tumorigenesis of several human cancers, such as medul-loblastoma, cholangiocarcinoma and prostate cancer (27–29). HDAC6 inhibitors are being tested both in preclinical settings and clinical trials as an anticancer agent (ClinicalTrials.gov Identifier: NCT01323751, NCT02091063, NCT02632071 and NCT02635061). However, the role of HDAC6 in lung adeno-carcinoma has not been well characterized. In the present study, we demonstrated that HDAC6 is overexpressed in lung adenocarcinoma cell lines and promotes the oncogen-esis of lung adenocarcinoma. HDAC6 also stabilized EGFR in lung adenocarcinoma cells. The inhibition of HDAC6 by CAY10603, a potent and selective HDAC6 inhibitor, induced apoptosis and impaired the proliferation of lung adenocarcinoma cells. Moreover, the inhibition of HDAC6 synergized with EGFR-TKIs to induce the apoptosis of lung adenocarcinoma cells via the suppression of EGFR pathway activation.
Although mounting evidence predicts a therapeutic benefit for HDAC inhibitors, we still face significant challenges in their clinical application. Broad spectrum HDAC inhibitors block multiple HDAC isoforms, particularly HDAC1 and HDAC3 (12,13). Although HDAC inhibitors have demonstrated significant antitumor effects, the profound side-effects associated with their use cannot be ignored. However, unlike the inhibition of other HDACs, the inhibition of HDAC6 is not believed to be associated with severe toxicity (30). Moreover, HDAC6 knockout in mice does not lead to embryonic lethality (31). Given that HDAC6 plays an important role in lung adenocarcinoma, the inhibition of HDAC6 may induce apoptosis in lung adenocarcinoma cells without the accompaniment of as many side-effects as broad spectrum HDAC inhibitors. Further studies that compare the antitumor efficiency and safety of HDAC6 inhibitors with broad spectrum HDAC inhibitors are needed, particularly in animal models.
EGFR plays a critical role in the control of cellular proliferation, differentiation and survival of lung adenocarcinoma cells. Activating mutations in EGFR such as exon 19 deletions and the L858R substitution in exon 21 are important markers of response to EGFR-TKI therapy in lung adenocar-cinoma (24). Acquired resistance to EGFR-TKIs is a major problem that continues to puzzle clinicians since the majority of patients who initially respond to therapy develop acquired resistance within 6–12 months. Several mechanisms that may be responsible for this acquired resistance have been identified, including a secondary T790M mutation in EGFR, c-Met amplification and transformation to SCLC (5). In addition to these well characterized mechanisms, further elucidation of novel mechanisms of acquired drug resistance is essential to overcome the problem of EGFR-TKI resistance. Furthermore, patients without EGFR mutations still manifest acquired resistance to EGFR inhibitors. Therefore, it remains urgent to explore additional mechanisms of acquired resistance to EGFR inhibitors. As mentioned above, the overexpression of HDAC6 stabilizes EGFR, while the inhibition of HDAC6 destabilizes EGFR. Here, we showed that overexpression of HDAC6 may partly account for the intrinsic resistance to EGFR-TKIs due to the activation of the EGFR pathway.
The kinase-independent role of EGFR has attracted increased attention in recent years. Zhang et al found that the survival of cancer cells can be maintained by EGFR independently of its kinase activity through the prevention of autophagic cell death of cancer cells (32). Thus, EGFR can still promote the survival of cancer cells when kinase activity is blocked by EGFR-TKIs. Acceleration of the degradation of EGFR may solve this problem, and the inhibition of HDAC6 can both destabilize EGFR and inhibit activation of the EGFR pathway. This may partly explain the synergistic effects of CAY10603 and gefitinib.
In summary, we report that HDAC6 is upregulated in lung adenocarcinoma and that inhibition of HDAC6 impairs the proliferation of lung adenocarcinoma cells. Moreover, the HDAC6 inhibitor CAY10603 synergizes with gefitinib to induce apoptosis in lung adenocarcinoma cells, which occurs partly through the destabilization of EGFR and inactivation of the EGFR pathway. Therefore, the inhibition of HDAC6 may be a potential strategy for treating lung adenocarcinoma and overcoming resistance to EGFR-TKIs.
AbbreviationsSCLC
small cell lung cancer
NSCLC
non-small cell lung cancer
HDACs
histone deacetylases
EGFR
epidermal growth factor receptor
TKIs
tyrosine kinase inhibitors
ERK
extracellular signal-regulated kinase
Hsp90
heat shock protein 90
PARP
poly(ADP-ribose) polymerase
SIRT
silent mating type information regulation 2 homolog
Acknowledgments
We acknowledge Professor Jun Zhou of the Nankai University for kindly providing the HDAC6 overexpression plasmids. The present study was supported by the Natural Sciences Foundation of Hubei Province (no. 2013CFA006).
ReferencesPaoWGirardNNew driver mutations in non-small-cell lung cancerLancet Oncol12175180201110.1016/S1470-2045(10)70087-521277552EttingerDSWoodDEAkerleyWBazhenovaLABorghaeiHCamidgeDRCheneyRTChirieacLRD'AmicoTADemmyTLNational comprehensive cancer networkNon-Small Cell Lung Cancer, Version 6.2015J Natl Compr Canc Netw13515524201525964637PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer10760774201010.1038/nrc2947209669213072803PopperHHRyskaATímárJOlszewskiWMolecular testing in lung cancer in the era of precision medicineTransl Lung Cancer Res32913002014PolitiKHerbstRSLung cancer in the era of precision medicineClin Cancer Res2122132220201510.1158/1078-0432.CCR-14-2748259799274505624ReckMHeigenerDFMokTSoriaJCRabeKFManagement of non-small-cell lung cancer: Recent developmentsLancet382709719201310.1016/S0140-6736(13)61502-023972814MinucciSPelicciPGHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNat Rev Cancer63851200610.1038/nrc177916397526HaberlandMMontgomeryRLOlsonENThe many roles of histone deacetylases in development and physiology: Implications for disease and therapyNat Rev Genet103242200910.1038/nrg2485FalkenbergKJJohnstoneRWHistone deacetylases and their inhibitors in cancer, neurological diseases and immune disordersNat Rev Drug Discov13673691201410.1038/nrd436025131830DuvicMOlsenEABrenemanDPachecoTRParkerSVonderheidECAbuavRRickerJLRizviSChenCEvaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphomaClin Lymphoma Myeloma9412416200910.3816/CLM.2009.n.08219951879MarksPABreslowRDimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drugNat Biotechnol258490200710.1038/nbt127217211407BruserudØStapnesCErsvaerEGjertsenBTRyningenAHistone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cellCurr Pharm Biotechnol8388400200710.2174/138920107783018417MarsoniSDamiaGCamboniGA work in progress: The clinical development of histone deacetylase inhibitorsEpigenetics3164171200810.4161/epi.3.3.625318487953KaliszczakMTrousilSÅbergOPerumalMNguyenQDAboagyeEOA novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growthBr J Cancer108342350201310.1038/bjc.2012.576233222053566806NamdarMPerezGNgoLMarksPASelective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agentsProc Natl Acad Sci USA1072000320008201010.1073/pnas.1013754107210371082993347KrämerOHMahboobiSSellmerADrugging the HDAC6-HSP90 interplay in malignanT cellsTrends Pharmacol Sci35501509201410.1016/j.tips.2014.08.00125234862ZhangYLiNCaronCMatthiasGHessDKhochbinSMatthiasPHDAC-6 interacts with and deacetylates tubulin and microtubules in vivoEMBO J2211681179200310.1093/emboj/cdg11512606581150348ParkSJKimJKBaeHJEunJWShenQKimHSShinWCYangHDLeeEKYouJSHDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancerCancer Lett35497106201410.1016/j.canlet.2014.07.04125111897Aldana-MasangkayGISakamotoKMThe role of HDAC6 in cancerJ Biomed Biotechnol2011875824201110.1155/2011/875824KozikowskiAPTapadarSLuchiniDNKimKHBilladeauDDUse of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6J Med Chem5143704373200810.1021/jm8002894186428923913184YangYRanJLiuMLiDLiYShiXMengDPanJOuGAnejaRCYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6Cell Res2413421353201410.1038/cr.2014.136253425594220159RanJYangYLiDLiuMZhouJDeacetylation of α-tubulin and cortactin is required for HDAC6 to trigger ciliary disassemblySci Rep512917201510.1038/srep12917GyőrffyBSurowiakPBudcziesJLánczkyAOnline survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancerPLoS One8e82241201310.1371/journal.pone.0082241YuHAArcilaMERekhtmanNSimaCSZakowskiMFPaoWKrisMGMillerVALadanyiMRielyGJAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res1922402247201310.1158/1078-0432.CCR-12-2246234709653630270DeribeYLWildPChandrashakerACurakJSchmidtMHKalaidzidisYMilutinovicNKratchmarovaIBuerkleLFetchkoMJRegulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6Sci Signal2ra84200920029029GaoYSHubbertCCYaoTPThe microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradationJ Biol Chem2851121911226201010.1074/jbc.M109.042754201339362856999GradiloneSARadtkeBNBogertPSHuangBQGajdosGBLaRussoNFHDAC6 inhibition restores ciliary expression and decreases tumor growthCancer Res7322592270201310.1158/0008-5472.CAN-12-2938233703273768151DhanyamrajuPKHolzPSFinkernagelFFendrichVLauthMHistone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathwayMol Cancer Ther14727739201510.1158/1535-7163.MCT-14-048125552369AiJWangYDarJALiuJLiuLNelsonJBWangZHDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancerMol Endocrinol2319631972200910.1210/me.2009-0188198550912796151HaggartySJKoellerKMWongJCGrozingerCMSchreiberSLDomain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylationProc Natl Acad Sci USA10043894394200310.1073/pnas.043097310012677000153564KaluzaDKrollJGesierichSYaoTPBoonRAHergenreiderETjwaMRössigLSetoEAugustinHGClass IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacety-lation of cortactinEMBO J3041424156201110.1038/emboj.2011.298218470943199386WeihuaZTsanRHuangWCWuQChiuCHFidlerIJHungMCSurvival of cancer cells is maintained by EGFR independent of its kinase activityCancer Cell13385393200810.1016/j.ccr.2008.03.015184551222413063
HDAC6 is upregulated in lung adenocarcinoma cell lines and is negatively correlated with the prognosis of patients with lung adenocarcinoma. (A) Western blot analysis of HDAC6 expression in three lung adenocarcinoma cell lines and the normal human lung cell line BEAS-2B. (B) The relationship between the expression of HDAC6 mRNA and the prognosis of patients with lung adenocarcinoma was analyzed using the Kaplan-Meier plotter database (version 2013) (23) (Kaplan-Meier plotter database website: http://kmplot.com/analysis/).
HDAC6 promotes the proliferation of lung adenocarcinoma cell lines. (A-D) Proliferation of A549 (A and C) and HCC827 (B and D) cells that were transfected with the indicated plasmids or siRNA was monitored by CCK-8 assay. NC, negative control.
HDAC6 confers resistance to gefitinib-mediated cell proliferation inhibition. (A-D) A549 (A and C) and HCC827 (B and D) cells were transfected with the indicated plasmids or siRNA. Then, 36 h after transfection, the cells were treated with the indicated concentrations of gefitinib. After another 48 h, cell viability was measured by CCK-8 assay. NC, negative control. **P<0.01, t-test.
Overexpression of HDAC6 confers resistance to gefitinib-induced apoptosis. (A) A549 and HCC827 cells were transfected with wild-type HDAC6 or mutated HDAC6. Then, 36 h after transfection, the cells were treated with gefitinib; 5 µM for A549 and 0.1 µM for HCC827. After another 48 h, cell apoptosis was detected by Annexin V staining (A) and western blotting (C). The percentage of apoptotic cells was derived from triplicate samples of Annexin V-positive cells as measured by flow cytometry (B). **P<0.01, t-test; ns, not significant.
Inhibition of HDAC6 by CAY10603 inhibits the proliferation of lung adenocarcinoma cells. (A) The chemical structure of the selective HDAC6 inhibitor, CAY10603 (CAY). (B and C) Curves show the dose-dependent effect of CAY10603 on the viability of A549 (B) and HCC827 cells (C). (D) The effect of CAY10603 on cell clone formation was measured by plate clone formation assay.
CAY10603 induces apoptosis of lung adenocarcinoma cells. (A and B) A549 cells were treated with the indicated doses of CAY10603 (CAY). After 48 h of treatment, cell apoptosis was detected by Annexin V staining (A) and western blotting (B). (C) Western blot analysis of a panel of anti-apoptotic and pro-apoptotic proteins in samples treated with different doses of CAY10603.
Inhibition of HDAC6 by CAY10603 synergizes with gefitinib to decrease the survival of A549 cells. (A) A549 cells were treated with the given doses of gefitinib (Gef) and 0.01 µM CAY10603 (CAY). Cell viability was measured by CCK-8 assay. (B-D) A549 cells were treated with 1 µM gefitinib and 0.01 µM CAY10603 for 48 h. Cell apoptosis was detected by Annexin V staining (B) and western blotting (D). The percentage of apoptotic cells was derived from triplicate samples of Annexin V-positive cells as measured by flow cytometry (C). (E) A549 cells were plated into 6-well plates and were treated with the indicated chemicals. Long-term survival was visualized after 7 days by crystal violet staining. One of three independent experiments is shown. **P<0.01, t-test.
HDAC6 stabilizes EGFR in a deacetylase activity-dependent manner and inhibition of HDAC6 inactivates the EGFR pathway. (A) A549 and HCC827 cells were transfected with wild-type HDAC6 or with mutated HDAC6. Then, 36 h after transfection, the cells were harvested for preparation of whole-cell protein lysates and subsequent western blot analysis. (B) A549 and HCC827 cells were transfected with negative control (NC) or HDAC6-specific siRNA. Then, 72 h after transfection, the cells were harvested for preparation of whole-cell protein lysates and subsequent western blot analysis. (C) Cells were treated with the indicated doses of CAY10603 (CAY). After 72 h of treatment, the cells were harvested for preparation of whole-cell protein lysates and subsequent western blot analysis. (D) A549 cells were plated in 6-well cell culture plates, and the next day, they were treated with 1 µM gefitinib (Gef) and 0.01 µM CAY10603, the cells were harvested for preparation of whole-cell protein lysates and subsequent western blot analysis.